A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
DOSE FINDING METHODS BASED ON CURE RATE MODEL IN PHASE I CANCER CLINICAL TRIALS Dose Finding Methods Based on Cure Rate Model in Phase I Cancer Clinical Trials
The main goal of a Phase I cancer clinical trial is to identify the maximum tolerated dose (MTD) of a new drug having acceptable dose-limiting toxicity (DLT). Two main model-based designs are continual reassessment method (CRM) (O'Quigley et al., 1990) and escalation with overdose control (EWOC) (Babb et al., 1998). Most of the designs are based on the binary toxic outcome. The occurrence of DLT is assessed over a predefined time window, and complete follow-up of the current patient is requiredfatcat:2svjig2h35arbdugrhp466p5dy